SCHEMBL8638786

SCHEMBL8638786

CNC(=O)c1ccccc1NC(=O)/C=C/c1ccc(OC)c(OC)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.79
ALDH1A1 P00352 5/20 0.79
MEN1 O00255 5/20 0.79
KMT2A Q03164 5/20 0.79
SMN1; SMN2 Q16637 4/20 0.79
KDM4E B2RXH2 4/20 0.79
NPSR1 Q6W5P4 3/20 0.79
NPC1 O15118 3/20 0.79
RAB9A P51151 3/20 0.79
TP53 P04637 2/20 0.79
CYP3A4 P08684 2/20 0.79
HIF1A Q16665 2/20 0.79
PKM P14618 2/20 0.79
CYP1A2 P05177 2/20 0.79
CYP2C9 P11712 1/20 0.79
CYP2C19 P33261 1/20 0.79
HSD17B10 Q99714 1/20 0.79
ABCC4 O15439 1/20 0.79
HPGDS O60760 1/20 0.79
ABCB11 O95342 1/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8638795 1.00 HPGD (0.79) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL8643612 0.91 ALDH1A1 (0.79) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL8643623 0.91 ALDH1A1 (0.79) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL13320668 0.89 ALDH1A1 (0.76) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2845939 0.88 MEN1 (0.82) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
Tranilast SCHEMBL29876 0.88 MEN1 (1.00) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
Tranilast SCHEMBL10978582 0.88 MEN1 (1.00) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL10497314 0.88 ALDH1A1 (0.82) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
Tranilast SCHEMBL8696829 0.88 MEN1 (1.00) HPGDALDH1A1MEN1KMT2ASMN1; SMN2
Tranilast SCHEMBL29875 0.88 MEN1 (1.00) HPGDALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1026543-A None JP disclosed
US-11583535-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation OCCURX PTY LTD (AU) 2023-02-21 US disclosed
US-20210244741-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION OCCURX PTY LTD (AU) 2021-08-12 US disclosed
US-10786510-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation OCCURX PTY LTD (AU) 2020-09-29 US disclosed
US-10695353-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation OCCURX PTY LTD (AU) 2020-06-30 US disclosed
EP-3485883-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION OccuRx Pty Ltd (AU) 2019-05-22 EP disclosed
US-20180117049-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION OCCURX PTY LTD (AU) 2018-05-03 US disclosed
US-20180117051-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION OCCURX PTY LTD (AU) 2018-05-03 US disclosed
US-9839640-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation OCCURX PTY LTD (AU) 2017-12-12 US disclosed
WO-2012068612-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION FIBROTECH THERAPEUTICS PTY LTD (AU) 2012-05-31 WO disclosed
EP-0855387-A1 2-ACYLAMINOBENZAMIDE DERIVATIVES AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY THE SUPERMULTIPLICATION OF VASCULAR INTIMAL CELLS KISSEI PHARMACEUTICAL CO., LTD. (JP) 1998-07-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180117049-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION VCAM1, PTGIS, NFKBIA HPGD 870/4885ALDH1A1 668/4885MEN1 3939/4885
US-20210244741-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION VCAM1, PTGIS, NFKBIA HPGD 870/4885ALDH1A1 668/4885MEN1 3939/4885
US-10695353-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation VCAM1, PTGIS, NFKBIA HPGD 870/4885ALDH1A1 668/4885MEN1 3939/4885
US-20180117051-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION VCAM1, PTGIS, NFKBIA HPGD 870/4885ALDH1A1 668/4885MEN1 3939/4885
US-11583535-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation VCAM1, PTGIS, NFKBIA HPGD 870/4885ALDH1A1 668/4885MEN1 3939/4885
US-10786510-B2 Methods of treating eye diseases associated with inflammation and vascular proliferation VCAM1, PTGIS, NFKBIA HPGD 870/4885ALDH1A1 668/4885MEN1 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.